Neuroactive steroid changes in response to challenge with the panicogenic agent pentagastrin

Psychoneuroendocrinology

Volumn 27, Issue 4, 2002, Pages 417-429

  Tait, Glendon R ^a   McManus, Karen ^a   Bellavance, François ^b   Nathalie Lara, ^a   Chrapko, Wendy ^a   Le Mellédo, Jean Michel ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b HEC MONTRÉAL   (Canada)

Author keywords

Allopregnanolone; Anxiety; Dehydroepiandrosterone; Gamma aminobutyric acid; Neuroactive steroids; Panic disorder

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ETHINYLESTRADIOL; PENTAGASTRIN; PRASTERONE; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HORMONE RESPONSE; HUMAN; MALE; PANIC; PLASMA; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL ANALYSIS; STEROID BLOOD LEVEL; STEROID RELEASE;

EID: 0036127644     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(01)00051-8     Document Type: Article

References (50)

1. Pentagastrin infusions in patients with panic disorder I. Symptoms and cardiovascular responses
2. Comorbidity of panic and depression: Implications for clinical management
3. A receptor function after acute stress
4. Stress-induced increase in brain neuroactive steroids: Antagonism with abecarnil
5. Allopregnanolone in woment with premenstrual syndrome
6. A receptor
7. Neurobiological investigations into the role of cholecystokinin in panic disorder
8. 2-induced panic attacks with cholecystokinin-induced panic attacks in PD
9. Enhanced sensitivity to cholecystokinin-tetrapeptide in panic disorder
10. Dose ranging study of the effects of cholecystokinin in healthy volunteers
11. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder
12. Spect (I-123) Iomazenil measurement of the benzodiazepene receptor in panic disorder
13. Agoraphobia with panic attacks: Development, diagnosis stability, and course of illness
14. Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind, placebo controlled study
15. Panic disorder during pregnancy
16. Oral contraceptives and panic disorder
17. Premenstrual exacerbation of symptoms in women with panic disorder
18. Comorbid psychiatric disorders in subjects with panic attacks
19. Estradiol treatment of panic disorder in a fertile aged woman
20. Steroid hormone metabolites are barbituate-like modulators of the GABA receptor
21. A receptor. Mechanism of action and physiological significance
22. Benzodiazepine receptor function in anxiety disorders
23. A-benzodiazepine receptor binding in panic disorder. Preliminary results from a quantitative PET study
24. Effect of ethinyl estradiol on the panic response to the panicogenic agent pentagastrin
25. Neuroactive steroids
26. Estrogen-induced panic attacks
27. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain
28. GABAergic agents and panic disorder
29. Differential anxiolytic effects of neurosteroids in the mirrored chamber behaviour test in mice
30. Progesterone metabolite allopregnanolone in women with premenstrual syndrome
31. Effects of antidepressant treatment on neuroactive steroids in major depression
32. Reduced benzodiazepine sensitivity in patients with panic disorder: Comparison with patients with obsessive-compulsive disorder and normal subjects
33. Neuroactive steroids: Mechanism of action and neuropsychopharmacological perspectives
34. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects
35. Neuroactive steroid levels in patients with generalized anxiety disorder
36. A receptor function in rat brain
37. A receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid
38. A receptor α4 subunit in association with increased anxiety
39. Elevated circulatory level of GABA(A)-antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder
40. Concentrations of the 3-α-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery
41. A case of panic disorder induced by oral contraceptive
42. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine
43. Pentagastrin induced panic attacks: Enhanced sensitivity in panic disorder patients
44. The cross-national epidemiology of panic disorder
45. Comparative behavioural characterization of the neuroactive steroids 3α-OH, 5α-pregnan-20-one and 3-α-OH, 5β-pregnan-20-one in rodents
46. Double-blind treatment of major depression with dehydroepiandrosterone